Powered by


                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS







   Forum Archives





















   Primary Care






   Other Sections


   Research Tools

   Medical Tutorials

   Medical Software




Back to index

Cancer Chemotherapy Regimen for Colon Cancer

 MOF-S                                                   colon(49)
  semustine....... 30 mg/sqm/day orally on days 1 to 5 inclusive.
  vincristine..... 1 mg IV day 1 and day 35 (5 weeks).
  fluorouracil.... 300 mg/sqm/day IV on days 1 to 5 and on days 35 
                   to 40, inclusive.
  streptozotocin.. 500 mg/sqm IV on day 1 and weekly thereafter.
  FREQUENCY....... Repeat cycle every 70 days (10 weeks).

    Kemeny N.  Yagoda A.  Braun D Jr.  Golbey R. Therapy for 
    metastatic colorectal carcinoma with a combination of 
    methyl-CCNU, 5-fluorouracil vincristine and streptozotocin 
    (MOF-Strep). Cancer.  45(5):876-81, 1980 Mar 1. 
    Seventy-seven previously untreated patients with measurable 
    metastatic colorectal carcinoma were treated with a 
    combination of methyl-CCNU, 5-fluorouracil (5-FU), vincristine 
    and streptozotocin (MOF-Strep). The treatment schedule 
    consisted of methyl-CCNU, 30 mg/m2 for 5 consecutive days q 10 
    weeks; 5-FU, 300 mg/m2 IV for five consecutive days q 5 weeks; 
    vincristine, 1 mg IV q 5 weeks; and streptozotocin, 500 mg/m2 
    IV weekly. Two (3%) patients achieved complete remission (CR); 
    22 (29%) patients, a partial remission (PR); and 13 (18%) 
    patients, a minor remission (MR). The median duration of 
    remission was eight months (range, 4-25+months) for patients 
    obtaining CR/PR status, and six months (range, 4-15 months) 
    for MR status. The median survival time was 14 months for 
    patients achieving CR/PR versus seven months for non 
    responders. Comparison with a previous study of MOF at 
    Memorial Sloan-Kettering Cancer Center, showed that the 
    MOF-Strep combination produced a significant (P = 0.004) 
    increase in the number of complete and partial remissions, 32% 
    versus 11%, and in survival, 11 versus 9 months, (P = 0.003), 
advertisement.gif (61x7 -- 0 bytes)

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


 advertisement.gif (61x7 -- 0 bytes)




We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.